A Novel Approach To Benchmarking Medication Errors In Pediatric Transplant Centers  by Shepherd, C.A. & Nieder, M.L.
Oral Presentations S195103
USE OF AN EDUCATION INTERVENTION IN IMPROVING BLOOD GLUCOSE
MANAGEMENT IN PATIENTS UNDERGOING ALLOGENEIC BLOOD AND
MARROW TRANSPLANTATION (BMT)
Ritzau, N., Wildridge, S., Shelburne, N., Feigenbaum, K., Aker, D. Na-
tional Institutes of Health, Bethesda, MD
Poor glycemic control in patients undergoing BMT is associated
with non-relapsemortality. Impaired immune function and infection
related to hyperglycemia, as well as increased morbidity and mortal-
ity associated with hypoglycemia and glucose variability have been
demonstrated. Medications utilized in the BMT population; e.g. ste-
roids and immunosuppressive agents, combined with the conditions
of neutropenia and type II or steroid induced diabetes mellitus, ne-
cessitates well coordinated blood glucose management in order to
improve overall patient outcomes.
The 28-bed adult allogeneic BMT unit at the National Institutes
of Health utilizes a BloodGlucoseManagement Service (BGMS), an
interdisciplinary, evidenced-based team of experts, to manage glyce-
mic control in this complex patient population. An analysis of point
of care testing and medication errors around glycemic control re-
vealed the majority of hospital wide errors occurred within the
BMT population. From January through March 2009 the BMT
unit alone contained 53% of all BGMS managed patients through-
out the hospital. In the same time period the average error rate
was 7% on the BMT unit, accounting for 91% of hospital blood glu-
cose management errors.
An evaluation of these errors highlighted communication with the
licensed independent practitioner and understanding of computer
based orders for blood glucose monitoring and insulin as areas for
improvement. BGMS emphasized the need for ongoing communica-
tion of patient changes, e.g. NPO status that require alterations in
dosing to the licensed independent practitioner, and correct reading
of real-time orders within the electronic medical record. An educa-
tion intervention, consisting of in-services held by the BGMS and
one on one targeted education of staff occurred in April andMay, re-
sulting in a decrease in error rates for June through August to an av-
erage of 2% on the BMT unit.
The successful implementation demonstrated by the drop in error
rate on the BMT unit led the BGMS to expand the education inter-
vention to additional hospital staff. Ongoing education of staff
through yearly competencies and targeted sessions will continue in
order to maintain a low error rate around glycemic control in
BMT. Ultimately this should result in improved patient safety and
clinical outcomes.104
A NOVEL APPROACH TO BENCHMARKING MEDICATION ERRORS IN PE-
DIATRIC TRANSPLANT CENTERS
Shepherd, C.A., Nieder, M.L. All Children’s Hospital, St. Petersburg, FL
Optimizing patient outcomes is paramount in blood and marrow
transplant programs. Although a multitude of risk factors certainly
contribute, these are patient-based attributes that cannot be
changed. However, reducing medication errors in the transplant
population can positively impact morbidity and mortality. Once in-
stitutions have identified best practices for medication error report-
ing, benchmarking these data appropriately can inform decisions
related to quality improvement. Much of the literature describing
medication errors has historically relied on a metric involving a ratio
of errors per medication doses dispensed. As with all programs, we
review and analyze this information on a monthly basis. However,
patient acuity is partly based on census and we believed that
a more appropriate metric should include this variable. Therefore,
in January 2009 we devised a new method for error analysis in our
blood and marrow transplant patient population.
Error Rate5 number of errors/(inpatient days) x 100
This rate is calculated monthly. We decided that 12 months of
data would be sufficient for defining our baseline. After 8 months
of trending, we have found the actual error rate to be 1.76 per
100 inpatient days. The monthly range has been 0.78 to 3.28.
The data thus far have not suggested a trend toward increased
medication errors occurring during higher census periods. In ad-
dition, we have not identified any specific trends related to errorcategory types (eg A, B, C) and patient census. After 12 months
of data collection, we plan to establish a baseline rate which can
be utilized to determine our program benchmark. Strategies for
improvement will center around error analysis and improving
system processes. Because of the small numbers of actual errors,
it will be necessary to collaborate with other pediatric transplant
programs to validate this methodology and to develop error re-
duction protocols.
Medication Errors 2009
MONTH # of ERRORS INPATIENT DAYS ERROR RATEJan 4 128 3.13
Feb 2 183 1.09
Mar 3 160 1.88
Apr 4 122 3.28
May 1 124 0.81
June 1 128 0.78
July 3 153 1.96
Aug 3 193 1.55TOTAL 21 1191 1.76** Year-To-Date Error Rate105
CASE CONTROL STUDY OF LEVETIRACETAM VS. FOSPHENYTOIN FOR
SEIZURE PROPHYLAXIS IN CHILDREN RECEIVING BUSULFAN (BU) FOR
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Skeens, M.A., Soni, S., Pai, V., Bajwa, R., Pietryga, D., Gross, T.,
Termuhlen, A. Nationwide Children’s Hospital, Columbus, OH; The
Ohio State University, Columbus, OH; The Ohio State University,
Columbus, OH; The Ohio State University, Columbus, OH
Background Busulfan (BU) is utilized frequently for myeloabla-
tion in children undergoing hematopoietic stem cell transplanta-
tion (HSCT). A 7-10% incidence of seizures has been reported
for patients receiving BU without any anti-convulsant prophylaxis.
The PK profile of Levetiracetam is favorable as an anti-convulsant
in this setting. This study compared levetiracetam and fospheny-
toin during BU, examining the effect on busulfan levels, efficiency
of administration (cost, nursing time, drug compatibility), and ef-
ficacy.
Methods We performed a retrospective case control study of fos-
phenytoin (n5 20) vs. levetiracetam (n5 27) use for seizure prophy-
laxis during BU conditioning regimens. Patients were matched by
age, gender, diagnosis, and type of HSCT. All patients received
BU at an initial dose of 0.8 mg/kg to 1 mg/kg, subsequently adjusted
to an AUC of 800-1350 mmol/L based on first dose PK. Levetirace-
tam was given at 10 mg/kg/dose (maximum: 500 mg/dose) intrave-
nously (IV) over 15 minutes every 12 hours. Initial doses were
administered 6 to 12 hours prior to first dose of BU and continued
at least 24 hours after the completion of BU. Fosphenytoin was ad-
ministered as a loading dose (15 mg PE/kg) 12-24 hours before BU
followed by age appropriate maintenance dosing with intermittent
loading doses for subtherapeutic levels. Fosphenytoin was given as
IV infusion (duration dependent on dose).
Results Median age for both groups was 8 years, with similar
ranges. Both groups contained 15% autologous and 85% alloge-
neic HSCT. Two seizures occurred in the case control vs. none
in the levetiracetam group. BU dose adjustments were required
in 20/27 (74%) patients receiving levetiracetam and in 15/20
(75%) fosphenytoin patients to attain AUC goal. Levetiracetam
was a shorter infusion, with no drug compatibility issues, level
monitoring, or dose adjustments when compared to fosphenytoin.
Cost analysis is pending.
Conclusion There is no previous report of using levetiracetam as
a single agent for seizure prophylaxis during a BU conditioning
regimen in pediatric HSCT patients. When compared to fosphe-
nytoin, in this small number of patients, there were no seizures.
Levetiracetam did not alter the frequency of BU dose adjustments
and is more efficient to administer. Further, prospective trials us-
ing levetiracetam as a single agent to prevent BU induced seizures
are needed.
